Attitudes, beliefs toward end-of-life care differ between hematologic, solid tumor specialists
the ONA take:
Researchers at the University of Texas MD Anderson Cancer Center conducted a survey to compare the attitudes and beliefs toward palliative care among hematologic versus solid tumor specialists.
They randomly surveyed 120 hematologists and 120 solid tumor oncologists at the institution; 182 clinicians (76%) responded.
The survey questions examined the participants’ attitudes toward various aspects of end-of-life care, including use of palliative systemic therapy.
The researchers found significant differences in attitudes and beliefs toward end-of-life care. Hematologic specialty and comfort level with prescribing treatment to patients with Eastern Cooperative Oncology Group performance status 4 and an expected survival of 1 month were associated with the decision to treat in the last month of life.
Survey compares attitudes and beliefs toward palliative care among hematologic versus solid tumor specialists.
- Ixazomib, a New PI, Offers Improved Efficacy With Acceptable Toxicity Profile for Relapsed/Refractory Multiple Myeloma
- Acupuncture May Improve Fatigue in Patients with Lung Cancer
- "Light" Cigarettes and Cancer Risk (Fact Sheet)
- A Review of CDK4/6 Toxicities and Interactions Management in Breast Cancer
- Vitamin D3 Supplementation Has No Impact on Breast Density Percentage, Breast Cancer Risk
- Dexamethasone-Induced Hiccups in Chemotherapy May be Prevented by Rotating to Methylprednisolone
- New Evidence Shows Metastases May Spread Independently of Lymph Nodes
- Long Term Survivors of Prostate Cancer Express Treatment Decision Regret for Up to 15 Years
- FDA Expands Clearance for Cooling Cap Use With Chemotherapy for Solid Tumors
- Recommendations for Vaccine Administration During Chemotherapy
- Palliative Cancer Care Should Focus on Symptoms, Not Diagnoses
- COX-2 Inhibitors Can Improve Response to Immunotherapy of Some Cancer Tumors
- Risk for Prostate Cancer Not Associated With Vasectomy, Meta-analysis Affirms
- Disease-Free Survival After Breast Cancer Comparable With Exemestane, Sequential Tamoxifen/Exemestane
- Treating the Other "Patient": Depressive Symptoms Are Predictive of Declining Physical Health in Caregivers
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|